Ikarian Capital’s Ovid Therapeutics OVID Stock Holding History

Ikarian Capital’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.43M	Buy	2,894,704 +2,647,146	+1,069%	+$4.73M	0.52%	50
2025 Q4	$404K	Sell	247,558 -848,016	-77%	-$1.31M	0.03%	142
2025 Q3	$1.42M	Buy	+1,095,574	New	+$950K	0.14%	110
2022 Q3	–	Sell	-26,831	Closed	-$59K	–	148
2022 Q2	$59K	Sell	26,831 -711,541	-96%	-$1.72M	0.01%	134
2022 Q1	$2.32M	Buy	738,372 +33,290	+5%	+$105K	0.3%	62
2021 Q4	$2.26M	Sell	705,082 -400,000	-36%	-$1.37M	0.34%	58
2021 Q3	$3.71M	Sell	1,105,082 -19,790	-2%	-$72.2K	0.26%	84
2021 Q2	$4.4M	Hold	1,124,872	–	–	0.36%	74
2021 Q1	$4.52M	Buy	+1,124,872	New	+$3.74M	0.15%	129
2020 Q2	–	Sell	-377,737	Closed	-$1.13M	–	200
2020 Q1	$1.13M	Buy	377,737 +27,737	+8%	+$93.5K	0.08%	116
2019 Q4	$1.45M	Buy	+350,000	New	+$1.11M	0.24%	70

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ikarian Capital's OVID Position: Q1 2026 in Review

Ikarian Capital increased its Ovid Therapeutics (OVID) stake by 1,069% in Q1 2026, buying an estimated $4.73M and bringing the position to 2,894,704 shares worth $6.43M. The position accounts for 0.52% of the portfolio, ranked #50.

Ikarian Capital first reported a position in OVID in Q4 2019 and has held it in 11 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Ikarian Capital held 2,894,704 shares of Ovid Therapeutics worth $6.43M as of Q1 2026.
Ikarian Capital bought 2,647,146 Ovid Therapeutics shares in Q1 2026, an estimated $4.73M.
Ovid Therapeutics made up 0.52% of Ikarian Capital's portfolio in Q1 2026, its #50 holding.
Ikarian Capital first reported a position in Ovid Therapeutics in Q4 2019 and has held it in 11 quarters since.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.